Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 41

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 41
---
401(k) plan under which we make matching contributions of up to $3,000 per employee per year. |
| ✔           |     | Independent compensation committee. Our compensation committee comprises solely independent members of our Board.                                                                                                               |     | ✘                  |     | No special health or welfare benefits.We do not provide our executives with any special health or welfare benefits. Our executive officers participate in the same broad-based company-sponsored health and welfare benefits programs made available to our other full-time, salaried employees.             |
| ✔           |     | Independent compensation consultant. Our compensation committee uses an independent compensation consultant that provides no other material services to the company.                                                            |     | ✘                  |     | Hedging, short selling and pledging prohibited.Our insider trading policy prohibits our executive officers and directors from hedging, short-selling or pledging our securities.                                                                                                                             |

27

TABLE OF CONTENTS

Competitive Market Review As described above, during 2024, the Compensation Committee engaged Alpine as its compensation consultant. As part of its engagement, the Compensation Committee requested that Alpine develop a comparative group of companies and to perform analyses of competitive performance and compensation levels for purposes of developing recommendations that were presented to the Compensation Committee for its consideration. In developing our peer group for 2024, the criteria used to identify the peer companies were business focus (i.e., companies with a similar therapeutic focus and patient population), market capitalization, headcount, and location. The 18 companies selected for our peer group for 2024 are listed below.

| Aclaris Therapeutics (ACRS)   |     | AnaptysBio (ANAB)                |     | Phantom Pharmaceuticals (PHAT) |
| Akero Therapeutics (AKRO)     |     | Arcellx (ACLX)                   |     | Pliant Therapeutics (PLRX)     |
| Allakos (ALLK)                |     | Cogent Biosciences (COGT)        |     | RAPT Therapeutics (RAPT)       |
| Allogene Therapeutics (ALLO)  |     | Crinetics Pharmaceuticals (CRNX) |     | Syndax Pharmaceuticals (SNDX)  |
| AlloVir (ALVR)                |     | CymaBay Therapeutics (CBAY)      |     | Terns Pharmaceuticals (TERN)   |
| Alpine Immune Sciences (ALPN) |     | IDEAYA Biosciences (IDYA)        |